Major genetic susceptibility for venous thromboembolism in men: a study of Danish twins.
نویسندگان
چکیده
BACKGROUND Although several genetic determinants (mutations or polymorphisms) have been associated with increased risk of venous thromboembolism, the overall influence of genetic factors on this disease is unknown. METHODS We linked the Danish Twin Registry, which includes twins born 1870-1953, with the Danish National Registry of Patients, comprising all hospitalizations in Denmark since 1977. We then determined the risk of venous thromboembolism as determined from discharge diagnosis. RESULTS We identified 26,982 twins who were alive on 1 January 1977, and computed measures of familial and genetic association of venous thrombotic disorders. Individuals were classified according to zygosity and hospitalization with venous thromboembolism. Since 1977, 678 twins were hospitalized with an episode of venous thromboembolism. Of these, only 545 pairs (281 male pairs and 264 female pairs) were alive in 1977. For men, the concordance rates for mono- and dizygotic twin pairs, respectively, were 0.22 (95% confidence interval = 0.14 to 0.30) and 0.08 (0.04-0.12). The odds ratio (interpreted as the relative risk of venous thromboembolism for one twin, given venous thromboembolism in the partner twin) was 13.5 (7.3-24.8) among monozygotic twins and 3.8 (1.8-8.3) among dizygotic twins. The respective correlations for venous thromboembolism were 0.55 (0.38-0.70) and 0.26 (0.09-0.42). The proportion of the variance attributable to genetic effects on venous thromboembolism in males was 55% (39%-68%). The remaining variation could be attributed to men's nonfamilial environments. In contrast, for women there was no intra-twin pair similarity for venous thromboembolism. CONCLUSIONS We found differences in genetic susceptibility to venous thromboembolism between the sexes, with genetic factors playing a substantially stronger role in males than in females.
منابع مشابه
Evaluation of the Frequency of Risk Factors in Venous Thromboembolic Patients Admitted to Ekbatan and Farshchian Hospitals in Hamadan from 2012 to 2017
Background and Objective: Venous thromboembolism is one of the major causes of mortality worldwide. Various environmental and genetic factors are known as risk factors for this disease. Therefore, this study aimed to investigate the frequency of risk factors in patients with venous thromboembolism admitted to Ekbatan and Farshchian hospitals in Hamadan from 2012 to 2017. Materials and Methods:...
متن کاملRisk factors for venous thromboembolism: Smoking, anthropometry, and genetic susceptibility PhD thesis
Objective: We validated discharge diagnoses of venous thromboembolism (VTE) in the Danish National Patient Registry. Study Design and Setting: We identified all first-time VTE discharge diagnoses in the Danish National Patient Registry among participants of the Danish cohort study ‘‘Diet, Cancer, and Health’’, in the period from 1994 to 2006. Medical records were retrieved and VTE diagnoses wer...
متن کاملبررسی نقش ریسک فاکتورهای ژنتیکی و اکتسابی در سرنوشت آمبولی ریه
Background: Pulmonary embolism (PE) and deep venous thrombosis (DVT) constitute one of the “big three” cardiovascular killers, along with myocardial infarction and stroke. Although thrombophilia play major and well documented role in pathogenesis of arterial and venous thromboembolism, but the effect of thrombophilia in biological fat of thromboembolism is not well recognized. The role of acq...
متن کاملFamilial risk of venous thromboembolism: a nationwide cohort study.
BACKGROUND Venous thromboembolism has genetic determinants, but population-based data on familial risks are limited. OBJECTIVES To examine the familial risk of venous thromboembolism. METHODS We undertook a nationwide study of a cohort of patients with deep venous thrombosis or pulmonary embolism born after 1952. We used the Danish National Registry of Patients covering all Danish hospitals...
متن کاملRivaroxaban versus enoxaparin for treatment of patients with nonhematologic cancer with venous thromboembolism a randomized clinial trial
Background: Low-Molecular-Weight Heparin (LMWH) is recommended as the first-line treatment in patients with active cancer and venous thromboembolism (VTE), but many patients prefer to take oral anticoagulants and non-injectable forms with more reasonable price. Venous thromboembolism is a very common comorbidity in patients with cancer. Therefore, the aim of this study was to evaluate the effic...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Epidemiology
دوره 14 3 شماره
صفحات -
تاریخ انتشار 2003